Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose RadioimmunoassayNestor M. · Ekberg T. · Dring J. · van Dongen G.A.M.S. · Wester K. · Tolmachev V. · Anniko M.
aUnit of Otolaryngology and Head and Neck Surgery, Department of Surgical Sciences, and bUnit of Biomedical Radiation Science, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden; cDepartment of Otolaryngology/Head and Neck Surgery, Free University Medical Center, Amsterdam, The Netherlands
Background: In the growing field of tumor targeting, there is an urgent need to profile suitable molecular targets. In this study, CD44v6 and EGFR expression was quantified in samples of patients with head and neck squamous cell carcinoma (HNSCC) using a single-dose (SD) radioimmunoassay. Methods: The SD radioimmunoassay using 125I-chimeric monoclonal antibody (cMAb) U36 and 125I-cMAb cetuximab was first validated and then applied to quantify the expression of their target antigen molecules, CD44v6 and EGFR, in patient samples. Results were compared to immunohistochemical staining. Results: The SD assay provided sensitive quantitative values of the molecular targets studied, generally agreeing with the immunohistochemistry (IHC) results. The results indicated that expression of CD44v6 (0.2–20 nmol/µg membrane) was generally higher than that of EGFR (0.6–2.3 nmol/µg membrane) in the tumor samples analyzed, which corresponded to an average of 700,000 and 90,000 antigen molecules per cell, respectively. Conclusions: The SD radioimmunoassay is simple, reliable, and can be performed on a small amount (50 mg) of tissue. This assay could be a useful tool in the growing field of personalized cancer therapy, and can be used as a complement to IHC. In the tumors studied, CD44v6 was generally expressed at a higher level than EGFR, which might suggest that it could be more readily targeted by MAbs.
Division of Biomedical Radiation Sciences
SE–751 85 Uppsala (Sweden)
Tel. +46 18 471 3868, Fax +46 18 471 3432, E-Mail Marika.Nestor@bms.uu.se
Received: March 26, 2007
Accepted after revision: June 15, 2007
Published online: November 9, 2007
Number of Print Pages : 11
Number of Figures : 6, Number of Tables : 2, Number of References : 30
Tumor Biology (Tumor Markers, Tumor Targeting and Translational Cancer Research)
Vol. 28, No. 5, Year 2007 (Cover Date: November 2007)
Journal Editor: Stigbrand, T. (Umeå)
ISSN: 1010–4283 (print), 1423–0380 (Online)
For additional information: http://www.karger.com/TBI